Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Industry News (Research)
Scientists Discuss Tumor Suppressor Gene Research
November 20th, 1995
Canji, Inc., San Diego, California, announced that it will present results from preclinical studies (in the form of three separate abstracts) at the Gene Therapy of Cancer meeting, held November 8-11, 1995, in San Diego. These results demonstrate the potential of Canji's tumor suppressor program to develop therapeutic products by supplying cancer cells with a new, normally functioning gene that can either block tumor growth or trigger the death of tumor cells. The first abstract demonstrates a gene-specific anti-tumor effect of Canji's p53 gene therapy treatment in a preclinical model of liver cancer and supports a strategy to evaluate p53 gene therapy of liver...
Source: Cancer Weekly (1995-11-20)
|
